Scancell (LON:SCLP) Shares Down 3.1% – Should You Sell?

Scancell Holdings plc (LON:SCLP)’s stock price dropped 3.1% on Friday . The stock traded as low as GBX 11.63 and last traded at GBX 12.50. Approximately 444,921 shares traded hands during trading, a decline of 74% from the average daily volume of 1,685,915 shares. The stock had previously closed at GBX 12.90.

Scancell Price Performance

The stock’s 50 day moving average price is GBX 12.87 and its 200-day moving average price is GBX 10.84. The company has a quick ratio of 13.01, a current ratio of 0.56 and a debt-to-equity ratio of -193.29. The stock has a market capitalization of £125.57 million, a PE ratio of -22.00 and a beta of 0.33.

Scancell (LON:SCLP) last posted its quarterly earnings results on Thursday, January 29th. The company reported GBX (0.55) EPS for the quarter. Scancell had a positive return on equity of 90.29% and a negative net margin of 116.98%. As a group, equities analysts forecast that Scancell Holdings plc will post -2.5361112 EPS for the current year.

About Scancell

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.